← Back to Clinical Trials
Recruiting NCT05200923

NCT05200923 Pelvic Health Electrically Evoked Recording (PEER) 2 Study

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05200923
Status Recruiting
Phase —
Sponsor MedtronicNeuro
Condition Overactive Bladder
Study Type INTERVENTIONAL
Enrollment 300 participants
Start Date 2022-01-18
Primary Completion 2026-12-18

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Sacral Neuromodulation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 300 participants in total. It began in 2022-01-18 with a primary completion date of 2026-12-18.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

To collect physiological signals at several timepoints during the therapy evaluation period.

Eligibility Criteria

Inclusion Criteria: Overactive Bladder Criteria Inclusion Criteria 1. 18 years of age or older 2. Candidate for or undergoing Medtronic InterStim lead implant for labeled indication\* requiring an advanced evaluation 3. Willing and able to provide signed and dated informed consent 4. Willing and able to independently and accurately complete diaries, questionnaires, attend visits, and comply with the study protocol 5. Willing to maintain current regimen (dosage and frequency) of any OAB medication from baseline diary through the end of therapy evaluation 6. For subjects with urinary urge incontinence, have a diagnosis of OAB as demonstrated on a voiding diary by having a minimum of 3 episodes of urinary urge incontinence in the first 72 hours (Episodes must have a mild, moderate, or severe degree of urgency to meet this criterion) of the voiding diary. 7. For subjects with urinary frequency, have a diagnosis of OAB as demonstrated on a voiding diary with greater than or equal to 8 urgency frequency episodes per day within the first 72 hours of the voiding diary. Note\*: Candidate for or undergoing a Medtronic InterStim lead implant for labeled indication means that a clinical decision has already been made between a physician and the patient to undergo Medtronic Interstim lead implant to treat the subject's condition. This decision is to be made prior to discussing with the patient whether to enroll in the study. Non-Obstructive Urinary Retention Inclusion Criteria 1. 18 years of age or older 2. Candidate for or undergoing Medtronic InterStim lead implant for labeled indication\* requiring an advanced evaluation 3. Willing and able to provide signed and dated informed consent 4. Willing and able to independently and accurately complete diaries, questionnaires, attend visits, and comply with the study protocol 5. Willing to maintain current regimen (dosage and frequency) of any NOUR medication from baseline diary through the end of therapy evaluation 6. Have a diagnosis of non-obstructive urinary retention with an elevated postvoid residual (PVR) that has persisted for at least six months and is documented on two or more separate occasions. Note\*: Candidate for or undergoing a Medtronic InterStim lead implant for labeled indication means that a clinical decision has already been made between a physician and the patient to undergo Medtronic Interstim lead implant to treat the subject's condition. This decision is to be made prior to discussing with the patient whether to enroll in the study. Fecal Incontinence Inclusion Criteria 1. 18 years of age or older 2. Candidate for or undergoing Medtronic InterStim lead implant labeled indication\* requiring an advanced evaluation 3. Willing and able to provide signed and dated informed consent 4. Willing and able to independently and accurately complete diaries, questionnaires, attend visits, and comply with the study protocol 5. Willing to maintain current regimen (dosage and frequency) of any FI medication from baseline diary through the end of therapy evaluation 6. Have a diagnosis of fecal incontinence as demonstrated by 3-day a bowel diary as greater than or equal to 1 incontinent episode of more than staining (i.e., either slight, moderate, or severe soiling) Note\*: Candidate for or undergoing a Medtronic InterStim lead implant for labeled indication means that a clinical decision has already been made between a physician and the patient to undergo Medtronic Interstim lead implant to treat the subject's condition. This decision is to be made prior to discussing with the patient whether to enroll in the study. Exclusion Criteria: Overactive Bladder Criteria Exclusion Criteria 1. Currently enrolled or planning to enroll in an interventional clinical study that could potentially confound the study results (co-enrollment in an interventional study is only allowed when documented pre-approval is obtained from the Medtronic study manager or designee) 2. Implanted with a neurostimulator, pacemaker or defibrillator 3. Pelvic floor muscle dysfunction due to surgical intervention or injury 4. Have neurological conditions such as multiple sclerosis, clinically significant peripheral neuropathy or spinal cord injury (e.g., paraplegia) 5. History of diabetes unless the diabetes is well-controlled through diet and/or medications 6. Have symptomatic urinary tract infection (UTI) 7. Have primary stress incontinence or mixed incontinence where the stress component overrides the urge component 8. Treatment of voiding behavior with botulinum toxin in the past 9 months or any plan to have botulinum toxin treatment during the study 9. Treatment of symptoms with tibial neuromodulation therapy in the last 3 months 10. Have knowledge of planned magnetic resonance imaging (MRIs) during the therapy evaluation portion of the study 11. Have knowledge of planned shortwave diathermy, microwave diathermy, or therapeutic diathermy 12. Women who are pregnant or planning to become pregnant 13. Current urinary tract mechanical obstruction (e.g. benign prostatic enlargement or urethral stricture) 14. Characteristics indicating a poor understanding of the study or characteristics that indicate the subject may have poor compliance with the study protocol requirements Non-Obstructive Urinary Retention Exclusion Criteria 1. Currently enrolled or planning to enroll in an interventional clinical study that could potentially confound the study results (co-enrollment in an interventional study is only allowed when documented pre-approval is obtained from the Medtronic study manager or designee) 2. Implanted with a neurostimulator, pacemaker or defibrillator 3. Pelvic floor muscle dysfunction due to surgical intervention or injury 4. Have neurological conditions such as multiple sclerosis, clinically significant peripheral neuropathy or spinal cord injury (e.g., paraplegia) 5. History of diabetes unless the diabetes is well-controlled through diet and/or medications 6. Have symptomatic urinary tract infection (UTI) 7. Treatment of symptoms with tibial neuromodulation therapy in the last 3 months 8. Have knowledge of planned magnetic resonance imaging (MRIs) during the therapy evaluation portion of the study 9. Have knowledge of planned shortwave diathermy, microwave diathermy, or therapeutic diathermy 10. Women who are pregnant or planning to become pregnant 11. Current urinary tract mechanical obstruction (e.g. benign prostatic enlargement or urethral stricture) 12. Characteristics indicating a poor understanding of the study or characteristics that indicate the subject may have poor compliance with the study protocol requirements Fecal Incontinence Exclusion Criteria 1. Currently enrolled or planning to enroll in an interventional clinical study that could potentially confound the study results (co-enrollment in an interventional study is only allowed when documented pre-approval is obtained from the Medtronic study manager or designee) 2. Implanted with a neurostimulator, pacemaker or defibrillator 3. Pelvic floor muscle dysfunction due to surgical intervention or injury 4. Have neurological conditions such as multiple sclerosis, clinically significant peripheral neuropathy or spinal cord injury (e.g., paraplegia) 5. Have uncorrected high grade internal rectal prolapse 6. Treatment of symptoms with tibial neuromodulation therapy in the last 3 months 7. Have knowledge of planned magnetic resonance imaging (MRIs) during the therapy evaluation portion of the study 8. Have knowledge of planned shortwave diathermy, microwave diathermy, or therapeutic diathermy 9. Women who are pregnant or planning to become pregnant 10. Characteristics indicating a poor understanding of the study or characteristics that indicate the subject may have poor compliance with the study protocol requirements

Contact & Investigator

Central Contact

Katherine Peterson

✉ katherine.r.peterson@medtronic.com

📞 414-704-4065

Principal Investigator

Katherine Peterson

STUDY DIRECTOR

Medtronic Pelvic Health

Frequently Asked Questions

Who can join the NCT05200923 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Overactive Bladder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05200923 currently recruiting?

Yes, NCT05200923 is actively recruiting participants. Contact the research team at katherine.r.peterson@medtronic.com for enrollment information.

Where is the NCT05200923 trial being conducted?

This trial is being conducted at Indianapolis, United States, New Orleans, United States, New Orleans, United States, Rochester, United States and 3 additional locations.

Who is sponsoring the NCT05200923 clinical trial?

NCT05200923 is sponsored by MedtronicNeuro. The principal investigator is Katherine Peterson at Medtronic Pelvic Health. The trial plans to enroll 300 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology